Table 3

Mortality risk based on presence of T2D and VFs at baseline, stratified by sex and BMI category

Outcome: death during follow-up, HR (95% CI)
Overall (N = 19,822)Men (N = 4,405)Women (N = 15,417)
Normal weight (N = 1,413)Overweight (N = 2,323)Obese (N = 643)Normal weight (N = 5,747)Overweight (N = 6,318)Obese (N = 3,204)
Without T2D or VFs (reference)1.01.01.01.01.01.01.0
With VFs alone1.20 (1.13– 1.27)1.09 (0.81–1.45)1.03 (0.81–1.31)1.08 (0.59–1.94)1.26 (1.15–1.39)1.24 (1.13–1.36)1.15 (1.01–1.32)
With T2D alone1.78 (1.65–1.91)1.84 (1.44–2.36)1.50 (1.21–1.84)1.22 (0.83–1.78)1.64 (1.39–1.95)2.04 (1.79–2.32)1.87 (1.62–2.15)
With both T2D and VFs2.05 (1.73–2.43)1.27 (0.46–3.48)2.42 (1.20– 4.88)3.11 (1.50–6.46)1.75 (1.23–2.47)2.32 (1.73–3.11)1.92 (1.37–2.68)
With T2D alone (reference)1.01.01.01.01.01.01.0
With both T2D and VFs1.21 (0.97–1.49)0.68 (0.24–1.93)1.61 (0.78–3.33)2.54 (1.17–5.51)1.06 (0.72–1.55)1.13 (0.82–1.55)1.03 (0.72–1.45)
With VFs alone (reference)1.01.01.01.01.01.01.0
With both T2D and VFs1.71 (1.43–2.03)1.15 (0.4–3.24)2.38 (1.15–4.96)3.1 (1.25–7.57)1.37 (0.97–1.95)1.86 (1.38–2.52)1.65 (1.16–2.34)
  • Individuals were assigned at baseline to four groups: without T2D or VFs, with T2D only, with VFs only, and with both T2D and VFs. A Cox regression model adjusted for age (natural splines with 5 df), corticosteroid use, antiosteoporotic treatment, and cohort, stratified for sex and BMI, was fitted to estimate the survival of the individuals based on their T2D and VF status at baseline.